Serum Institute Of India Pvt. Ltd.

This study tested a new malaria vaccine combination (Pfs230D1 and R21 with Matrix-M) in 240 healthy African adults aged 18-50. The goal was to check safety and immune response. The vaccine aims to prevent both malaria infection and transmission.